# US 2026/0184819 A1 · Tetravalent Bispecific Antibody, Preparation Method Therefor, and Use Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0184819 A1
- Document ID: US20260184819A1
- Status: Published application
- Kind: A1
- Application number: 19/566,570
- Filed: 2026-03-13
- Published: 2026-07-02
- Earliest claimed: 2020-04-29
- Assignees: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- Applicants: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- Inventors: Jie Zhao; Haomin Huang; Zhenping Zhu; Yunxia Zhu
- Web page: https://patentgrep.com/patent/US20260184819A1

## CPC

- C07K 16/22: against growth factors {; against growth regulators}
- A61K 40/30: characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61P 35/00: Antineoplastic agents
- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 16/2818: {against CD28 or CD152}
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- C07K 16/34: against blood group antigens
- C07K 16/468: {Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/35: Valency
- C07K 2317/51: Complete heavy chain or Fd fragment, i.e. VH + CH1
- C07K 2317/515: Complete light chain, i.e. VL + CL
- C07K 2317/55: Fab or Fab'
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided are a structurally symmetrical tetravalent bispecific antibody based on a common light chain and a construction method therefor. The prepared tetravalent bispecific antibody has similar or even better biological activity and physical and chemical properties than monoclonal antibodies, and can be used for the treatment of various inflammatory diseases, cancer, and other diseases.

## Claims

### Claim at position 1

1-40. (canceled)

### Claim 41

A tetravalent bispecific antibody against PD-1/LAG-3, wherein the tetravalent bispecific antibody comprises two polypeptide chains and four common light chains, an amino acid sequence of the polypeptide chain is shown as SEQ ID NO. 143, and an amino acid sequence of the common light chain is shown as SEQ ID NO. 129.

### Claim 42 (depends on 41)

An isolated nucleotide, wherein the nucleotide encodes the tetravalent bispecific antibody against PD-1/LAG-3 of claim 41.

### Claim 43 (depends on 42)

The isolated nucleotide of claim 42, wherein a sequence of the nucleotide encoding the polypeptide chain is shown as SEQ ID NO. 144, and a sequence of the nucleotide encoding the common light chain is shown as SEQ ID NO. 130.

### Claim 44 (depends on 42)

An expression vector, wherein the expression vector comprises the nucleotide of claim 42.

### Claim 45 (depends on 44)

The expression vector of claim 44, wherein a sequence of the nucleotide encoding the polypeptide chain is shown as SEQ ID NO. 144, and a sequence of the nucleotide encoding the common light chain is shown as SEQ ID NO. 130.

### Claim 46 (depends on 42)

A host cell, wherein the host cell comprises the isolated nucleotide of claim 42.

### Claim 47 (depends on 46)

The host cell of claim 46, wherein a sequence of the nucleotide encoding the polypeptide chain is shown as SEQ ID NO. 144, and a sequence of the nucleotide encoding the common light chain is shown as SEQ ID NO. 130.

### Claim 48 (depends on 44)

A host cell, wherein the host cell comprises the expression vector of claim 44.

### Claim 49 (depends on 48)

The host cell of claim 48, wherein a sequence of the nucleotide encoding the polypeptide chain is shown as SEQ ID NO. 144, and a sequence of the nucleotide encoding the common light chain is shown as SEQ ID NO. 130.

### Claim 50 (depends on 41)

A pharmaceutical composition, wherein the pharmaceutical composition comprises the tetravalent bispecific antibody against PD-1/LAG-3 of claim 41.

### Claim 51 (depends on 41)

A method for treating cancer, inflammatory disease, or an autoimmune disease, the method comprising administering to a subject in need thereof the tetravalent bispecific antibody against PD-1/LAG-3 of claim 41.

### Claim 52 (depends on 51)

The method of claim 51, wherein the subject suffers from cancer.

### Claim 53 (depends on 50)

A method for treating cancer, inflammatory disease, or an autoimmune disease, the method comprising administering to a subject in need thereof the pharmaceutical composition of claim 50.

### Claim 54 (depends on 53)

The method of claim 53, wherein the subject suffers from cancer.

### Claim 55 (depends on 41)

A method of preparing the tetravalent bispecific antibody against PD-1/LAG-3 of claim 41, wherein the method comprises the following steps:
a) constructing an expression vector containing an isolated nucleotide that encodes the tetravalent bispecific antibody against PD-1/LAG-3 of claim 41, and transforming a host cell;
b) culturing the host cell of step a) under expression conditions, to express the tetravalent bispecific antibody against PD-1/LAG-3;
c) isolating and purifying the tetravalent bispecific antibody against PD-1/LAG-3 of step b).

### Claim 56 (depends on 55)

The method of claim 55, wherein a sequence of the nucleotide encoding the polypeptide chain is shown as SEQ ID NO. 144, and a sequence of the nucleotide encoding the common light chain is shown as SEQ ID NO. 130.
